A cancer drug is turning heads in autoimmune disease treatment. Teclistamab, a bispecific antibody approved for multiple myeloma, triggered major clinical responses in over 60% of patients with severe, treatment-resistant autoimmune conditions. The catch? Cytokine release syndrome hit two-thirds of patients, and infections and hypogammaglobulinemia were common, raising important safety flags.
A cancer drug is making waves in autoimmune disease treatment. Teclistamab (Tecvayli), a B-cell maturation antigen (BCMA)-directed bispecific antibody originally approved for multiple myeloma, was tested in 18 patients with severe, treatment-refractory autoimmune diseases — including systemic sclerosis, lupus, and inflammatory myopathies — across five European centers. The results? Major clinical responses in 61% of patients, with an additional 22% achieving minimal-to-moderate responses.
But the safety picture is complicated. Cytokine release syndrome (CRS) occurred in 67% of patients, infections were equally common, and all patients with available follow-up developed severe hypogammaglobulinemia — dangerously low antibody levels that left them vulnerable to illness. Two patients also developed severe noninfectious colitis, and fatal events occurred in patients with advanced cardiac involvement.
Key Takeaways:
Why it matters: Teclistamab could open a new frontier for patients who've exhausted standard autoimmune therapies — but its significant toxicity profile means it's not ready for broad use. Experts stress it should only be administered at experienced centers with specialized teams.
